PRESS RELEASE | Basel, Switzerland, October 4, 2021

Versameb at Sachs 21st Annual Biotech in Europe Forum

• Isabel Ferreira speaking on the “Platform Technologies and Novel Therapeutics” Panel

Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs, today announces its participation in the  21^st Annual Biotech in Europe Forum organized by SACHS Associates taking place virtually 7^th-8^th October 2021.

Isabel Ferreira, Chief Business Officer of Versameb AG will be participating in a panel discussion titled “Platform Technologies & Novel Therapeutics” taking place at 14.40 CET on 7^th October 2021 and chaired by Bibhash Mukhopadhyay, Independent and Stefan Luzi, Partner at Gilde Healthcare Partners. Other panelists include Frauke Hein, Co-Founder & CBO, Adrenomed AG, Lynn Durham, Founder & CEO, STALICLA SA, Mike Romanos, Co-Founder & CEO, Microbiotica Ltd. and Yochi Slonim, Co-Founder & CEO, Anima Biotech, Inc.

Contact for media enquiries:

Versameb
Dr Klaas Zuideveld, CEO
ir@versameb.com

Optimum Strategic Communications
Mary Clark, Stella Lempidaki, Zoe Bolt
Tel: +44 (0)20 3950 9144
versameb@optimumcomms.com

DOWNLOAD PDF
– English